-
1
-
-
0032961099
-
The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors
-
Augustyns K, Bal G, Thonus G, Belyaev A, Zhang XM, Bollaert W, Lambeir AM, Durinx C, Goossens F & Haemers A 1999 The unique properties of dipeptidyl-peptidase IV (DPP IV/CD26) and the therapeutic potential of DPP IV inhibitors. Current Medicinal Chemistry 6 311-327.
-
(1999)
Current Medicinal Chemistry
, vol.6
, pp. 311-327
-
-
Augustyns, K.1
Bal, G.2
Thonus, G.3
Belyaev, A.4
Zhang, X.M.5
Bollaert, W.6
Lambeir, A.M.7
Durinx, C.8
Goossens, F.9
Haemers, A.10
-
2
-
-
0037974604
-
Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance
-
Conarello SL, Li ZH, Ronan J, Roy RS, Zhu L, Jiang GQ, Liu F, Woods J, Zycband E, Moller DE et al. 2003 Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. PNAS 100 6825-6830.
-
(2003)
PNAS
, vol.100
, pp. 6825-6830
-
-
Conarello, S.L.1
Li, Z.H.2
Ronan, J.3
Roy, R.S.4
Zhu, L.5
Jiang, G.Q.6
Liu, F.7
Woods, J.8
Zycband, E.9
Moller, D.E.10
-
3
-
-
0036188070
-
Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs
-
Deacon CF, Wamberg S, Bie P, Hughes TE & Holst JJ 2002 Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. Journal of Endocrinology 172 355-362.
-
(2002)
Journal of Endocrinology
, vol.172
, pp. 355-362
-
-
Deacon, C.F.1
Wamberg, S.2
Bie, P.3
Hughes, T.E.4
Holst, J.J.5
-
4
-
-
0035051327
-
Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters
-
Durinx C, Neels H, Van der Auwera JC, Naelaerts K, Scharpe S & De Meester I 2001 Reference values for plasma dipeptidyl-peptidase IV activity and their association with other laboratory parameters. Clinical Chemistry and Laboratory Medicine 39 155-159.
-
(2001)
Clinical Chemistry and Laboratory Medicine
, vol.39
, pp. 155-159
-
-
Durinx, C.1
Neels, H.2
Van der Auwera, J.C.3
Naelaerts, K.4
Scharpe, S.5
De Meester, I.6
-
5
-
-
0026794360
-
Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme
-
Erickson RH, Suzuki Y, Sedlmayer A & Kim YS 1992 Biosynthesis and degradation of altered immature forms of intestinal dipeptidyl peptidase IV in a rat strain lacking the enzyme. Journal of Biological Chemistry 267 21623-21629.
-
(1992)
Journal of Biological Chemistry
, vol.267
, pp. 21623-21629
-
-
Erickson, R.H.1
Suzuki, Y.2
Sedlmayer, A.3
Kim, Y.S.4
-
7
-
-
36849040001
-
Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice
-
Flock G, Baggio LL, Longuet C & Drucker DJ 2007 Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice. Diabetes 56 3006-3013.
-
(2007)
Diabetes
, vol.56
, pp. 3006-3013
-
-
Flock, G.1
Baggio, L.L.2
Longuet, C.3
Drucker, D.J.4
-
8
-
-
36148955109
-
Mechanisms of progression of chronic kidney disease
-
Fogo AB 2007 Mechanisms of progression of chronic kidney disease. Pediatric Nephrology 22 2011-2022.
-
(2007)
Pediatric Nephrology
, vol.22
, pp. 2011-2022
-
-
Fogo, A.B.1
-
9
-
-
34247874561
-
Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes
-
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I & Dejager S 2007 Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50 1148-1155.
-
(2007)
Diabetologia
, vol.50
, pp. 1148-1155
-
-
Fonseca, V.1
Schweizer, A.2
Albrecht, D.3
Baron, M.A.4
Chang, I.5
Dejager, S.6
-
10
-
-
6344241190
-
Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents
-
Green BD, Gault VA, O'Harte FPM & Flatt PR 2004a Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Current Pharmaceutical Design 10 3651-3662.
-
(2004)
Current Pharmaceutical Design
, vol.10
, pp. 3651-3662
-
-
Green, B.D.1
Gault, V.A.2
O'Harte, F.P.M.3
Flatt, P.R.4
-
11
-
-
1842530457
-
N-terminal His (7)-modification of glucagon-like peptide-1 (7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity
-
Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, Greer B, O'Harte FPM & Flatt PR 2004b N-terminal His (7)-modification of glucagon-like peptide-1 (7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. Journal of Endocrinology 180 379-388.
-
(2004)
Journal of Endocrinology
, vol.180
, pp. 379-388
-
-
Green, B.D.1
Mooney, M.H.2
Gault, V.A.3
Irwin, N.4
Bailey, C.J.5
Harriott, P.6
Greer, B.7
O'Harte, F.P.M.8
Flatt, P.R.9
-
12
-
-
33748531290
-
Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1
-
Green BD, Irwin N, Duffy NA, Gault VA, O'Harte FPM & Flatt PR 2006 Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1. European Journal of Pharmacology 547 192-199.
-
(2006)
European Journal of Pharmacology
, vol.547
, pp. 192-199
-
-
Green, B.D.1
Irwin, N.2
Duffy, N.A.3
Gault, V.A.4
O'Harte, F.P.M.5
Flatt, P.R.6
-
13
-
-
31844443202
-
Glucagon-like peptide-1: From extract to agent. The Claude Bernard Lecture, 2005
-
Holst JJ 2006 Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 49 253-260.
-
(2006)
Diabetologia
, vol.49
, pp. 253-260
-
-
Holst, J.J.1
-
14
-
-
20244373352
-
Analysis of rat insulin II promoter-ghrelin transgenic mice and rat glucagon promoter-ghrelin transgenic mice
-
Iwakura H, Hosoda K, Son C, Fujikura J, Tomita T, Noguchi M, Ariyasu H, Takaya K, Masuzaki H, Ogawa Y et al. 2005 Analysis of rat insulin II promoter-ghrelin transgenic mice and rat glucagon promoter-ghrelin transgenic mice. Journal of Biological Chemistry 280 15247-15256.
-
(2005)
Journal of Biological Chemistry
, vol.280
, pp. 15247-15256
-
-
Iwakura, H.1
Hosoda, K.2
Son, C.3
Fujikura, J.4
Tomita, T.5
Noguchi, M.6
Ariyasu, H.7
Takaya, K.8
Masuzaki, H.9
Ogawa, Y.10
-
15
-
-
45849115827
-
Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension
-
Jackson EK & Mi Z 2008 Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 51 1637-1642.
-
(2008)
Hypertension
, vol.51
, pp. 1637-1642
-
-
Jackson, E.K.1
Mi, Z.2
-
17
-
-
17844374375
-
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes
-
Lindsay JR, Duffy NA, McKillop AM, Ardill J, O'Harte FPM, Flatt PR & Bell PM 2005 Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes. Diabetic Medicine 22 654-657.
-
(2005)
Diabetic Medicine
, vol.22
, pp. 654-657
-
-
Lindsay, J.R.1
Duffy, N.A.2
McKillop, A.M.3
Ardill, J.4
O'Harte, F.P.M.5
Flatt, P.R.6
Bell, P.M.7
-
18
-
-
12144289077
-
Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion
-
Lugari R, Dei Cas A, Ugolotti D, Barilli AL, Camellini C, Ganzerla GC, Luciani A, Salerni B, Mittenperger F, Nodari S et al. 2004 Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion. Hormone and Metabolic Research 36 111-115.
-
(2004)
Hormone and Metabolic Research
, vol.36
, pp. 111-115
-
-
Lugari, R.1
Dei Cas, A.2
Ugolotti, D.3
Barilli, A.L.4
Camellini, C.5
Ganzerla, G.C.6
Luciani, A.7
Salerni, B.8
Mittenperger, F.9
Nodari, S.10
-
19
-
-
21344451403
-
Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus
-
Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I, Cremasco F, Ognibene A & Rotella C 2005 Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 48 1168-1172.
-
(2005)
Diabetologia
, vol.48
, pp. 1168-1172
-
-
Mannucci, E.1
Pala, L.2
Ciani, S.3
Bardini, G.4
Pezzatini, A.5
Sposato, I.6
Cremasco, F.7
Ognibene, A.8
Rotella, C.9
-
20
-
-
37149047560
-
GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet
-
McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA & Flatt PR 2007 GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. American Journal of Physiology. Endocrinology and Metabolism 293 E1746-E1755.
-
(2007)
American Journal of Physiology. Endocrinology and Metabolism
, vol.293
-
-
McClean, P.L.1
Irwin, N.2
Cassidy, R.S.3
Holst, J.J.4
Gault, V.A.5
Flatt, P.R.6
-
21
-
-
37549030476
-
Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1 (7-36) amide degradation in type 2 diabetic subjects
-
McKillop AM, Duffy NA, Lindsay JR, O'Harte FPM, Bell PM & Flatt PR 2008 Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1 (7-36) amide degradation in type 2 diabetic subjects. Diabetes Research and Clinical Practice 79 79-85.
-
(2008)
Diabetes Research and Clinical Practice
, vol.79
, pp. 79-85
-
-
McKillop, A.M.1
Duffy, N.A.2
Lindsay, J.R.3
O'Harte, F.P.M.4
Bell, P.M.5
Flatt, P.R.6
-
22
-
-
0034473089
-
Natural substrates of dipeptidyl peptidase IV
-
De Meester I, Durinx C, Bal G, Proost P, Struyf S, Goossens F, Augustyns K & Scharpe S 2000 Natural substrates of dipeptidyl peptidase IV. Advances in Experimental Medicine and Biology 477 67-87.
-
(2000)
Advances in Experimental Medicine and Biology
, vol.477
, pp. 67-87
-
-
De Meester, I.1
Durinx, C.2
Bal, G.3
Proost, P.4
Struyf, S.5
Goossens, F.6
Augustyns, K.7
Scharpe, S.8
-
23
-
-
0034090145
-
Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose
-
Meneilly GS, Demuth HU, McIntosh CHS & Pederson RA 2000 Effect of ageing and diabetes on glucose-dependent insulinotropic polypeptide and dipeptidyl peptidase IV responses to oral glucose. Diabetic Medicine 17 346-350.
-
(2000)
Diabetic Medicine
, vol.17
, pp. 346-350
-
-
Meneilly, G.S.1
Demuth, H.U.2
McIntosh, C.H.S.3
Pederson, R.A.4
-
24
-
-
0033619675
-
Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides
-
Mentlein R 1999 Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regulatory Peptides 85 9-24.
-
(1999)
Regulatory Peptides
, vol.85
, pp. 9-24
-
-
Mentlein, R.1
-
25
-
-
45749095401
-
Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes
-
Mikhail N 2008 Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. Expert Opinion on Investigational Drugs 17 845-853.
-
(2008)
Expert Opinion on Investigational Drugs
, vol.17
, pp. 845-853
-
-
Mikhail, N.1
-
26
-
-
0035985294
-
Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: Study using a Fischer 344 rat substrain deficient in its enzyme activity
-
Mitani H, Takimoto M, Hughes TE & Kimura M 2002 Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: study using a Fischer 344 rat substrain deficient in its enzyme activity. Japanese Journal of Pharmacology 88 442-450.
-
(2002)
Japanese Journal of Pharmacology
, vol.88
, pp. 442-450
-
-
Mitani, H.1
Takimoto, M.2
Hughes, T.E.3
Kimura, M.4
-
27
-
-
0036068322
-
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
-
Miyawaki K, Yamada Y, Ban N, Ihara Y, Tsukiyama K, Zhou HY, Fujimoto S, Oku A, Tsuda K, Toyokuni S et al. 2002 Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nature Medicine 8 738-742.
-
(2002)
Nature Medicine
, vol.8
, pp. 738-742
-
-
Miyawaki, K.1
Yamada, Y.2
Ban, N.3
Ihara, Y.4
Tsukiyama, K.5
Zhou, H.Y.6
Fujimoto, S.7
Oku, A.8
Tsuda, K.9
Toyokuni, S.10
-
28
-
-
34548379454
-
Management of dyslipidemias in patients with diabetes and chronic kidney disease
-
Molitch ME 2006 Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clinical Journal of the American Society of Nephrology 1 1090-1099.
-
(2006)
Clinical Journal of the American Society of Nephrology
, vol.1
, pp. 1090-1099
-
-
Molitch, M.E.1
-
29
-
-
0141737555
-
Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells
-
Pala L, Mannucci E, Pezzatini A, Ciani S, Sardi J, Raimondi L, Ognibene A, Cappadona A, Vannelli BG & Rotella CM 2003 Dipeptidyl peptidase-IV expression and activity in human glomerular endothelial cells. Biochemical and Biophysical Research Communications 310 28-31.
-
(2003)
Biochemical and Biophysical Research Communications
, vol.310
, pp. 28-31
-
-
Pala, L.1
Mannucci, E.2
Pezzatini, A.3
Ciani, S.4
Sardi, J.5
Raimondi, L.6
Ognibene, A.7
Cappadona, A.8
Vannelli, B.G.9
Rotella, C.M.10
-
30
-
-
0037342614
-
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats
-
Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CHS & Pederson RA 2003 Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 741-750.
-
(2003)
Diabetes
, vol.52
, pp. 741-750
-
-
Pospisilik, J.A.1
Martin, J.2
Doty, T.3
Ehses, J.A.4
Pamir, N.5
Lynn, F.C.6
Piteau, S.7
Demuth, H.U.8
McIntosh, C.H.S.9
Pederson, R.A.10
-
31
-
-
33749064594
-
Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake
-
Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J & Vilsboll T 2006 Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. European Journal of Endocrinology 155 485-493.
-
(2006)
European Journal of Endocrinology
, vol.155
, pp. 485-493
-
-
Ryskjaer, J.1
Deacon, C.F.2
Carr, R.D.3
Krarup, T.4
Madsbad, S.5
Holst, J.6
Vilsboll, T.7
-
32
-
-
0026498840
-
Biochemical and immunological properties of urinary angiotensinase A and dipeptidyla-minopeptidase IV - their use as markers in patients with renal cell injury
-
Scherberich JE, Wiemer J & Schoeppe W 1992 Biochemical and immunological properties of urinary angiotensinase A and dipeptidyla-minopeptidase IV - their use as markers in patients with renal cell injury. European Journal of Clinical Chemistry and Clinical Biochemistry 30 663-668.
-
(1992)
European Journal of Clinical Chemistry and Clinical Biochemistry
, vol.30
, pp. 663-668
-
-
Scherberich, J.E.1
Wiemer, J.2
Schoeppe, W.3
-
33
-
-
23844504364
-
Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: A model for type 2 diabetes and pharmacological screening
-
Srinivasan K, Viswanad B, Asrat L, Kaul CL & Ramarao P 2005 Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharmacological Research 52 313-320.
-
(2005)
Pharmacological Research
, vol.52
, pp. 313-320
-
-
Srinivasan, K.1
Viswanad, B.2
Asrat, L.3
Kaul, C.L.4
Ramarao, P.5
-
34
-
-
0026088951
-
A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein - use as a liver-cell transplantation model
-
Thompson NL, Hixson DC, Callanan H, Panzica M, Flanagan D, Faris RA, Hong WJ, Hartel-Schenk S & Doyle D 1991 A Fischer rat substrain deficient in dipeptidyl peptidase IV activity makes normal steady-state RNA levels and an altered protein - use as a liver-cell transplantation model. Biochemical Journal 273 497-502.
-
(1991)
Biochemical Journal
, vol.273
, pp. 497-502
-
-
Thompson, N.L.1
Hixson, D.C.2
Callanan, H.3
Panzica, M.4
Flanagan, D.5
Faris, R.A.6
Hong, W.J.7
Hartel-Schenk, S.8
Doyle, D.9
-
35
-
-
0037777695
-
1- (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: A potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties
-
Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME & Hughes TE 2003 1- (3-hydroxy-1-adamantyl) amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. Journal of Medicinal Chemistry 46 2774-2789.
-
(2003)
Journal of Medicinal Chemistry
, vol.46
, pp. 2774-2789
-
-
Villhauer, E.B.1
Brinkman, J.A.2
Naderi, G.B.3
Burkey, B.F.4
Dunning, B.E.5
Prasad, K.6
Mangold, B.L.7
Russell, M.E.8
Hughes, T.E.9
-
36
-
-
0037205175
-
Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats
-
Yasuda N, Nagakura T, Yamazaki K, Inoue T & Tanaka I 2002 Improvement of high fat-diet-induced insulin resistance in dipeptidyl peptidase IV-deficient Fischer rats. Life Sciences 71 227-238.
-
(2002)
Life Sciences
, vol.71
, pp. 227-238
-
-
Yasuda, N.1
Nagakura, T.2
Yamazaki, K.3
Inoue, T.4
Tanaka, I.5
-
37
-
-
0347064086
-
Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets - a common mechanism for glucose toxicity and lipotoxicity?
-
Zhou YP, Marlen K, Palma JF, Schweitzer A, Reilly L, Gregoire FM, Xu GG, Blume JE & Johnson JD 2003 Overexpression of repressive cAMP response element modulators in high glucose and fatty acid-treated rat islets - a common mechanism for glucose toxicity and lipotoxicity? Journal of Biological Chemistry 278 51316-51323.
-
(2003)
Journal of Biological Chemistry
, vol.278
, pp. 51316-51323
-
-
Zhou, Y.P.1
Marlen, K.2
Palma, J.F.3
Schweitzer, A.4
Reilly, L.5
Gregoire, F.M.6
Xu, G.G.7
Blume, J.E.8
Johnson, J.D.9
|